Who
Sergey Yurasov
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Black Diamond Therapeutics; Chief Medical Officer, Nuvation Bio; Sr. VP, Clinic. Devel. & CMO, Immune Design.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $11K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 1 Oct 2016
- Last trade
- 21 Jan 2026
- Last filed
- 23 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Jan 2026filed 23 Jan 2026 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 30 Jan 2025filed 31 Jan 2025 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 30 Jan 2025filed 31 Jan 2025 | BDTX Black Diamond TherapeuticsBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 14 Feb 2024filed 15 Feb 2024 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 13 Feb 2023filed 15 Feb 2023 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 10 Feb 2021filed 12 Feb 2021 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —398,935 | filing |
| 10 Feb 2021filed 12 Feb 2021 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —398,935 | filing |
| 2 Apr 2019filed 4 Apr 2019 | Immune Designoption or derivative | SEC FORM 4 Code D | —72,620 | filing |
| 2 Apr 2019filed 4 Apr 2019 | Immune Designoption or derivative | SEC FORM 4 Code D | —110,000 | filing |
| 2 Apr 2019filed 4 Apr 2019 | Immune Designoption or derivative | SEC FORM 4 Code D | —113,335 | filing |
| 2 Apr 2019filed 4 Apr 2019 | Immune Designoption or derivative | SEC FORM 4 Code D | —110,000 | filing |
| 2 Apr 2019filed 4 Apr 2019 | Immune Design | SEC FORM 4 Code D | $36K6,136 at $5.85 | filing |
| 7 Jan 2019filed 7 Jan 2019 | Immune Design | SEC FORM 4 Sold | $5,5303,522 at $1.57 | filing |
| 3 Jan 2019filed 7 Jan 2019 | Immune Designoption or derivative | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 3 Jan 2019filed 7 Jan 2019 | Immune Design | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 7 Nov 2018filed 9 Nov 2018 | Immune Design | SEC FORM 4 Code A | —29,953 at $0.00 | filing |
| 17 Jul 2018filed 19 Jul 2018 | Immune Designoption or derivative | SEC FORM 4 Code D | —52,768 | filing |
| 17 Jul 2018filed 19 Jul 2018 | Immune Designoption or derivative | SEC FORM 4 Code A | —35,179 | filing |
| 17 Jul 2018filed 19 Jul 2018 | Immune Designoption or derivative | SEC FORM 4 Code D | —87,232 | filing |
News
No headline names them, or the companies they trade most, lately.